Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD 20.45
-0.57 (-2.71%)
Aug 28, 2026, 4:10 PM AEST
Neuren Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 69.51 | 64.63 | 136.73 | 231.93 | 14.55 | - |
Other Revenue | 0.02 | 0.02 | 80.11 | 0.02 | 0.86 | 3.2 |
| 69.53 | 64.65 | 216.83 | 231.94 | 15.42 | 3.2 | |
Revenue Growth | -68.23% | -70.19% | -6.51% | 1404.46% | 382.23% | 345.89% |
Cost of Revenue | 48.92 | 36.39 | 32.97 | 26.75 | 12.71 | 9.52 |
Gross Profit | 20.61 | 28.26 | 183.86 | 205.19 | 2.71 | -6.32 |
Selling, General & Admin | 6.75 | 6.22 | 4.7 | 5.95 | 3.44 | 1.91 |
Operating Expenses | 6.75 | 6.22 | 4.7 | 5.95 | 3.44 | 1.91 |
Operating Income | 13.86 | 22.04 | 179.16 | 199.25 | -0.73 | -8.23 |
Interest & Investment Income | 11.43 | 12.16 | 11.01 | 5.69 | 0.39 | 0.04 |
Currency Exchange Gain (Loss) | 6.91 | 8.03 | -7.24 | 2.43 | 1.23 | 0.4 |
Other Non Operating Income (Expenses) | -5.38 | -3.3 | - | -2.23 | -0.7 | - |
EBT Excluding Unusual Items | 26.81 | 38.93 | 182.94 | 205.14 | 0.18 | -7.79 |
Pretax Income | 26.81 | 38.93 | 182.94 | 205.14 | 0.18 | -7.79 |
Income Tax Expense | 6.56 | 8.49 | 40.9 | 48.06 | - | - |
Net Income | 20.26 | 30.44 | 142.04 | 157.08 | 0.18 | -7.79 |
Net Income to Common | 20.26 | 30.44 | 142.04 | 157.08 | 0.18 | -7.79 |
Net Income Growth | -86.41% | -78.57% | -9.57% | 85270.11% | - | - |
Shares Outstanding (Basic) | 128 | 128 | 128 | 127 | 126 | 118 |
Shares Outstanding (Diluted) | 130 | 131 | 131 | 131 | 129 | 119 |
Shares Change | - | -0.01% | 0.01% | 1.44% | 8.76% | 10.71% |
EPS (Basic) | 0.16 | 0.24 | 1.11 | 1.24 | 0.00 | -0.07 |
EPS (Diluted) | 0.16 | 0.23 | 1.09 | 1.20 | 0.00 | -0.07 |
EPS Growth | -86.41% | -78.57% | -9.58% | 120020.00% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 5.08 | 125.39 | -11.28 | 184.89 | 3.58 | -9.98 |
Free Cash Flow Per Share | 0.04 | 0.96 | -0.09 | 1.41 | 0.03 | -0.08 |
Gross Margin | 29.64% | 43.71% | 84.80% | 88.47% | 17.55% | -197.65% |
Operating Margin | 19.94% | 34.09% | 82.63% | 85.90% | -4.75% | -257.52% |
Profit Margin | 29.13% | 47.08% | 65.51% | 67.72% | 1.19% | -243.79% |
Free Cash Flow Margin | 7.30% | 193.95% | -5.20% | 79.71% | 23.22% | -312.17% |
EBITDA | 13.89 | 22.06 | 179.18 | 199.26 | -0.72 | -8.23 |
EBITDA Margin | 19.98% | 34.13% | 82.64% | 85.91% | -4.68% | -257.27% |
D&A For EBITDA | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
EBIT | 13.86 | 22.04 | 179.16 | 199.25 | -0.73 | -8.23 |
EBIT Margin | 19.94% | 34.09% | 82.63% | 85.90% | -4.75% | -257.52% |
Effective Tax Rate | 24.45% | 21.82% | 22.36% | 23.43% | - | - |
Revenue as Reported | 87.86 | 84.84 | 227.85 | 240.06 | 17.03 | 3.64 |